Primary Hyperoxaluria Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Precision Biosciences, Chinook Therapeutics, BridgeBio, OxThera

Primary Hyperoxaluria Pipeline constitutes 6+ key companies continuously working towards developing 6+ Primary Hyperoxaluria treatment therapies, analyzes DelveInsight.

Primary Hyperoxaluria Overview:

Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder caused by a deficiency of the liver enzyme alanine-glyoxylate aminotransferase, leading to excessive oxalate production. This results in high oxalate excretion in urine and calcium oxalate accumulation in organs, particularly the kidneys. PH1 is the most severe and common form, with an estimated prevalence of 1-3 cases per million and an incidence of 1 per 120,000 births annually in Europe.

The disorder is characterized by kidney stone formation, potential kidney damage, and systemic complications if untreated. Symptoms include severe pain in the lower abdomen, groin, or back, discolored urine, painful or frequent urination, and systemic signs like fever, nausea, and vomiting. If unmanaged, PH1 can lead to kidney failure.

Primary hyperoxaluria results from genetic mutations affecting glyoxylate metabolism, with PH1 linked to the AGXT gene, PH2 to GRHPR, and PH3 to HOGA1. Excess oxalate forms insoluble calcium oxalate deposits in various organs, including the kidneys, heart, blood vessels, skin, and bones, leading to systemic oxalosis. Without proper management, the disease can cause progressive kidney and systemic complications.

Request for a detailed insights report on Primary Hyperoxaluria pipeline insights @ https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Primary Hyperoxaluria Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Primary Hyperoxaluria Therapeutics Market.

Key Takeaways from the Primary Hyperoxaluria Pipeline Report

DelveInsight's Primary Hyperoxaluria pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Primary Hyperoxaluria treatment.
Key Primary Hyperoxaluria companies such as Precision Biosciences, Chinook Therapeutics, BridgeBio, OxThera, and others are evaluating new drugs for Primary Hyperoxaluria to improve the treatment landscape.
Promising Primary Hyperoxaluria pipeline therapies in various stages of development include Oxabact, and others.

Recent breakthroughs in the Primary Hyperoxaluria Pipeline Segment:
In September 2023, the FDA approved nedosiran, marketed as Rivfloza, for individuals aged nine and older with PH1 and relatively preserved kidney function. As an LDHA-directed small interfering RNA, nedosiran effectively lowers urinary oxalate levels.
Approved in November 2020 by both the U.S. Food and Drug Administration (FDA) and the European Union, lumasiran is an RNA interference therapeutic indicated for treating Primary Hyperoxaluria Type 1 (PH1) in adults and children. Clinical trials demonstrated a substantial reduction in urinary oxalate levels among treated patients.

Primary Hyperoxaluria Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Primary Hyperoxaluria Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Hyperoxaluria treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Primary Hyperoxaluria market.

Download our free sample page report on Primary Hyperoxaluria pipeline insights @ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Primary Hyperoxaluria Emerging Drugs

Oxabact: OxThera

Primary Hyperoxaluria Companies

Around six or more key companies are working on developing therapies for Primary Hyperoxaluria. Among them, OxThera has a drug candidate in the most advanced stage of development, Phase III.

DelveInsight's report covers around 6+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Primary Hyperoxaluria Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Primary Hyperoxaluria Therapies and Key Companies: Primary Hyperoxaluria Clinical Trials and advancements @ https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Primary Hyperoxaluria Pipeline Therapeutic Assessment
• Primary Hyperoxaluria Assessment by Product Type
• Primary Hyperoxaluria By Stage
• Primary Hyperoxaluria Assessment by Route of Administration
• Primary Hyperoxaluria Assessment by Molecule Type

Download Primary Hyperoxaluria Sample report to know in detail about the Primary Hyperoxaluria treatment market @ Primary Hyperoxaluria Therapeutic Assessment @ https://www.delveinsight.com/sample-request/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Primary Hyperoxaluria Current Treatment Patterns
4. Primary Hyperoxaluria - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Primary Hyperoxaluria Late-Stage Products (Phase-III)
7. Primary Hyperoxaluria Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Primary Hyperoxaluria Discontinued Products
13. Primary Hyperoxaluria Product Profiles
14. Primary Hyperoxaluria Key Companies
15. Primary Hyperoxaluria Key Products
16. Dormant and Discontinued Products
17. Primary Hyperoxaluria Unmet Needs
18. Primary Hyperoxaluria Future Perspectives
19. Primary Hyperoxaluria Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Primary Hyperoxaluria Pipeline Reports Offerings: https://www.delveinsight.com/report-store/primary-hyperoxaluria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.